Hearing Reconstruction of Patients with Otitis Media Based on Hydroxyapatite Nanomaterials
Journal of Biomedical Nanotechnology · 01.08.2022 · 18 (8) · 1986-1993
DOI: 10.1166/jbn.2022.3367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomedical Nanotechnology, erschienen am 01.08.2022. Verfasst von Yuenong Jiao und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
In this study, we conducted experiments on surgical methods and selection of osseous bone materials to study the hearing reconstruction of otitis media patients. The use of complete Bi mastoid mastectomy in patients with combined tympanoplasty was revealed for the pure tone air conduction valve, bone auditory valve and air bone conduction difference, which were 63.5, 32.5 and 34.9 respectively in preoperative values, and 27.6, 21 and 8.3 in the postoperative values. In addition, it was shown by the results that the artificial osseous material is better for the postoperative hearing reconstruction. In conclusion, our data suggests that hydroxyapatite nanomaterials have a tremendously positive effect on hearing reconstruction in patients with otitis media, and will certainly become one of the best choices for artificial osseous bone materials.
Zitieren
APA
Jiao, Y., Lin, Y., & Yu, F. (2022). Hearing Reconstruction of Patients with Otitis Media Based on Hydroxyapatite Nanomaterials. Journal of Biomedical Nanotechnology, 18(8), 1986-1993. https://doi.org/10.1166/jbn.2022.3367
Vancouver
Jiao Y, Lin Y, Yu F. Hearing Reconstruction of Patients with Otitis Media Based on Hydroxyapatite Nanomaterials. Journal of Biomedical Nanotechnology. 2022;18(8):1986-1993. doi:10.1166/jbn.2022.3367
BibTeX
@article{Jiao2022,
author = {Jiao, Yuenong and Lin, Ying and Yu, Feng},
title = {Hearing Reconstruction of Patients with Otitis Media Based on Hydroxyapatite Nanomaterials},
journal = {Journal of Biomedical Nanotechnology},
year = {2022},
volume = {18},
number = {8},
pages = {1986--1993},
doi = {10.1166/jbn.2022.3367}
}
EUVIMED